おすすめの製品
product name
Ascentis® Express Peptide ES C18キャピラリーHPLCカラム, 2.7 μm particle size, L × I.D. 15 cm × 1 mm
物質
stainless steel column
認証
suitable for USP L1
製品種目
Ascentis®
特徴
endcapped: no
メーカー／製品名
Ascentis®
包装
1 ea of
パラメーター
≤100 °C temp. range
テクニック
HPLC: suitable
LC/MS: suitable
UHPLC-MS: suitable
UHPLC: suitable
L × 内径
15 cm × 1 mm
表面積
90 m2/g
不純物
<5 ppm metals
マトリックス
Fused-Core particle platform
superficially porous particle
マトリックス活性基
C18 (octadecyl) phase
粒径
2.7 μm
ポアサイズ
160 Å
pH範囲
1-9
分離法
reversed phase
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
法的情報
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
試験成績書（COA）
Lot/Batch Number
Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）